Trending...
- NextBoat's AI-Powered Marine Marketplace Gains Momentum as Record Growth Signals an Inflection Point for Investors (N Y S E American: NXB)
- Allstream Energy Partners Returns as a Media Partner for the 2026 API Inspection & Mechanical Integrity Summit in San Antonio
- Heritage at Manalapan Introduces Luxury Single-Family Homes with Exceptional Value in One of Monmouth County's Most Desirable Locations
Potential DARPA Award, FDA-Authorized Phase 2/3 Trial, Breakthrough Therapy NRX-101, and Robotic-Enabled TMS Platform Highlight Expanding Opportunities for NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)
MIAMI - ncarol.com -- DARPA Selects NRx Defense Systems for Potential Clinical Trial Award Negotiations
FDA-Authorized Phase 2/3 SPARC-TMS Trial to Evaluate Robotic TMS Combined with Breakthrough Therapy NRX-101
Planned Study Includes Harvard McLean Hospital, HOPE Therapeutics Clinics, and Walter Reed National Military Medical Center
Expanding Government Partnerships Could Strengthen NRx Pharmaceuticals' Precision Neuropsychiatry Platform
Mental health remains one of the U.S. military's most significant healthcare priorities, with depression, PTSD, traumatic brain injury, and suicide continuing to impact active-duty service members, veterans, and first responders. As the Department of Defense seeks innovative technologies capable of improving treatment outcomes, NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP has announced a potentially significant milestone that could further strengthen its position in advanced neuropsychiatric medicine.
According to a Form 8-K filed on July 22, 2026, NRx Pharmaceuticals announced that its newly formed research and development subsidiary, NRx Defense Systems, Inc. (NRXD), has been selected by the Defense Advanced Research Projects Agency (DARPA), Defense Sciences Office (DSO) for contract negotiations regarding a potential clinical trial award.
While negotiations remain ongoing and no award has yet been finalized, management believes the selection reflects growing recognition of the company's innovative approach to treating severe depression through the combination of pharmaceutical therapy and advanced neurostimulation technologies.
DARPA Selects SPARC-TMS Proposal for Award Negotiations
On July 21, 2026, DARPA notified NRx Defense Systems that its proposal entitled Synaptic Plasticity Augmented Rapid Circuit Stimulation (SPARC-TMS) had been selected for negotiation of a potential award.
DARPA is widely recognized for supporting high-impact technologies with potential national defense applications, and selection for award negotiations represents an important milestone in the agency's competitive evaluation process.
The proposed clinical program is designed to evaluate whether robotic-enabled Transcranial Magnetic Stimulation (TMS) combined with NRX-101 can improve remission rates in patients suffering from severe depression.
The announcement represents another step in NRx Pharmaceuticals' strategy of combining advanced medical technologies, precision psychiatry, and pharmaceutical innovation into an integrated treatment platform for complex neuropsychiatric disorders.
More on ncarol.com
FDA-Authorized Phase 2/3 Trial Already in Place
Importantly, the SPARC-TMS protocol has already received authorization from the U.S. Food and Drug Administration as a Phase 2/3 clinical trial and has been listed on ClinicalTrials.gov under NCT07227103.
The study is designed to evaluate robotic-enabled TMS administered alongside NRX-101, the company's proprietary combination therapy consisting of D-cycloserine and lurasidone.
NRX-101 previously received Breakthrough Therapy Designation from the FDA for suicidal treatment-resistant bipolar depression, reflecting the agency's recognition that the therapy may offer meaningful advantages over existing treatment options for a serious medical condition.
By combining pharmaceutical treatment with advanced neurostimulation technology, investigators hope to demonstrate improved remission rates while further advancing the science of precision psychiatry.
Collaboration with Leading Medical and Military Institutions
The proposed study brings together several highly regarded clinical institutions.
According to the company's filing, the trial is expected to include:
The inclusion of both leading academic institutions and military healthcare facilities highlights the broad interest in developing innovative therapies capable of addressing some of the most challenging psychiatric conditions affecting both civilian and military populations.
Management believes these collaborations may also provide important clinical validation while expanding future opportunities within government healthcare systems.
HOPE Therapeutics Continues Expanding Commercial Platform
The DARPA announcement also complements the continued growth of HOPE Therapeutics, NRx Pharmaceuticals' wholly owned interventional psychiatry subsidiary.
HOPE Therapeutics already provides advanced treatments including ketamine therapy, Spravato®, Transcranial Magnetic Stimulation, Hyperbaric Oxygen Therapy, and other neuroplastic medicine protocols through its growing clinic network.
Earlier this year, HOPE Therapeutics became the first commercial site to deploy the FDA-cleared Zeta TMS Navigation System, utilizing artificial intelligence and image-guided technology to improve treatment precision for patients with Major Depressive Disorder and other neurological conditions.
More on ncarol.com
Should the DARPA-supported program move forward, HOPE Therapeutics clinics are expected to play an important role in executing the SPARC-TMS clinical program.
Expanding Government and Defense Opportunities
The formation of NRx Defense Systems represents an expansion of the company's strategy into military and government-sponsored medical research.
Federal agencies have increasingly prioritized innovative approaches to treating depression, PTSD, suicide risk, and other behavioral health conditions affecting military personnel and veterans.
Selection by DARPA for contract negotiations may position NRx Pharmaceuticals to participate more directly in these initiatives while supporting development of therapies that could have both military and civilian applications.
A Growing Precision Psychiatry Ecosystem
The DARPA announcement further strengthens what has become a diversified neuropsychiatric platform that extends beyond traditional pharmaceutical development.
Today, NRx Pharmaceuticals is advancing:
Together, these initiatives position the company across multiple segments of the rapidly evolving mental health market.
Looking Ahead
The selection of NRx Defense Systems by DARPA for contract negotiations represents another meaningful milestone in NRx Pharmaceuticals' ongoing evolution from a clinical-stage biotechnology company into a broader precision neuropsychiatry and commercial mental health organization.
If negotiations successfully result in a contract award, the SPARC-TMS program could further validate the company's integrated treatment strategy while expanding opportunities within military medicine and government-sponsored healthcare research.
Combined with continued progress across HOPE Therapeutics, advancement of NRX-101, commercialization initiatives, and expanding strategic partnerships, the DARPA announcement adds another potential catalyst for investors following NRx Pharmaceuticals as the company continues executing on its long-term growth strategy.
For more information on $NRXP visit: https://www.nrxpharma.com/ and https://compasslivemedia.com/case-study/nrx-pharmaceuticals/
Company Contact
NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)
Matthew Duffy – Chief Business Officer
Phone: (484) 254-6134
Email: mduffy@nrxpharma.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
FDA-Authorized Phase 2/3 SPARC-TMS Trial to Evaluate Robotic TMS Combined with Breakthrough Therapy NRX-101
Planned Study Includes Harvard McLean Hospital, HOPE Therapeutics Clinics, and Walter Reed National Military Medical Center
Expanding Government Partnerships Could Strengthen NRx Pharmaceuticals' Precision Neuropsychiatry Platform
Mental health remains one of the U.S. military's most significant healthcare priorities, with depression, PTSD, traumatic brain injury, and suicide continuing to impact active-duty service members, veterans, and first responders. As the Department of Defense seeks innovative technologies capable of improving treatment outcomes, NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP has announced a potentially significant milestone that could further strengthen its position in advanced neuropsychiatric medicine.
According to a Form 8-K filed on July 22, 2026, NRx Pharmaceuticals announced that its newly formed research and development subsidiary, NRx Defense Systems, Inc. (NRXD), has been selected by the Defense Advanced Research Projects Agency (DARPA), Defense Sciences Office (DSO) for contract negotiations regarding a potential clinical trial award.
While negotiations remain ongoing and no award has yet been finalized, management believes the selection reflects growing recognition of the company's innovative approach to treating severe depression through the combination of pharmaceutical therapy and advanced neurostimulation technologies.
DARPA Selects SPARC-TMS Proposal for Award Negotiations
On July 21, 2026, DARPA notified NRx Defense Systems that its proposal entitled Synaptic Plasticity Augmented Rapid Circuit Stimulation (SPARC-TMS) had been selected for negotiation of a potential award.
DARPA is widely recognized for supporting high-impact technologies with potential national defense applications, and selection for award negotiations represents an important milestone in the agency's competitive evaluation process.
The proposed clinical program is designed to evaluate whether robotic-enabled Transcranial Magnetic Stimulation (TMS) combined with NRX-101 can improve remission rates in patients suffering from severe depression.
The announcement represents another step in NRx Pharmaceuticals' strategy of combining advanced medical technologies, precision psychiatry, and pharmaceutical innovation into an integrated treatment platform for complex neuropsychiatric disorders.
More on ncarol.com
- New from Regal House Publishing, St. Ulphia's Dead, a dark comedy in the magical realist tradition
- New Novel WINCE Takes Unflinching Aim at American Gun Culture and Masculinity
- New Research Puts the Cost of Enterprise Decision Delay at $630 Billion a Year Across the Global 2000
- Cover Story about Matthew Cossolotto – Author of Harness Your PromisePower -- Published in July 2026 Enterprise World Magazine
- Lineus Medical Signs Partnership Agreement with DIMA MedTech to Support Expansion into Italy
FDA-Authorized Phase 2/3 Trial Already in Place
Importantly, the SPARC-TMS protocol has already received authorization from the U.S. Food and Drug Administration as a Phase 2/3 clinical trial and has been listed on ClinicalTrials.gov under NCT07227103.
The study is designed to evaluate robotic-enabled TMS administered alongside NRX-101, the company's proprietary combination therapy consisting of D-cycloserine and lurasidone.
NRX-101 previously received Breakthrough Therapy Designation from the FDA for suicidal treatment-resistant bipolar depression, reflecting the agency's recognition that the therapy may offer meaningful advantages over existing treatment options for a serious medical condition.
By combining pharmaceutical treatment with advanced neurostimulation technology, investigators hope to demonstrate improved remission rates while further advancing the science of precision psychiatry.
Collaboration with Leading Medical and Military Institutions
The proposed study brings together several highly regarded clinical institutions.
According to the company's filing, the trial is expected to include:
- Harvard McLean Hospital
- HOPE Therapeutics clinics operated by NRx Pharmaceuticals
- Walter Reed National Military Medical Center
- Additional designated military treatment facilities
The inclusion of both leading academic institutions and military healthcare facilities highlights the broad interest in developing innovative therapies capable of addressing some of the most challenging psychiatric conditions affecting both civilian and military populations.
Management believes these collaborations may also provide important clinical validation while expanding future opportunities within government healthcare systems.
HOPE Therapeutics Continues Expanding Commercial Platform
The DARPA announcement also complements the continued growth of HOPE Therapeutics, NRx Pharmaceuticals' wholly owned interventional psychiatry subsidiary.
HOPE Therapeutics already provides advanced treatments including ketamine therapy, Spravato®, Transcranial Magnetic Stimulation, Hyperbaric Oxygen Therapy, and other neuroplastic medicine protocols through its growing clinic network.
Earlier this year, HOPE Therapeutics became the first commercial site to deploy the FDA-cleared Zeta TMS Navigation System, utilizing artificial intelligence and image-guided technology to improve treatment precision for patients with Major Depressive Disorder and other neurological conditions.
More on ncarol.com
- New Research: Deterministic Decompilation of Hermes Bytecode Back to Readable JavaScript
- Lionheart Holdings and KEO Energy Sign Letter of Intent for Proposed Business Combination
- First Flight Society Celebrates National Aviation Day 2026 on Wednesday, August 19th
- Marcus Christ Announces Singles: "The Hammer Goes Click" and "You Hate Me, I Hate You"
- Nina Simone and Samuel Waymon Music Scholarship Fund Opens 2026/27 Application Cycle
Should the DARPA-supported program move forward, HOPE Therapeutics clinics are expected to play an important role in executing the SPARC-TMS clinical program.
Expanding Government and Defense Opportunities
The formation of NRx Defense Systems represents an expansion of the company's strategy into military and government-sponsored medical research.
Federal agencies have increasingly prioritized innovative approaches to treating depression, PTSD, suicide risk, and other behavioral health conditions affecting military personnel and veterans.
Selection by DARPA for contract negotiations may position NRx Pharmaceuticals to participate more directly in these initiatives while supporting development of therapies that could have both military and civilian applications.
A Growing Precision Psychiatry Ecosystem
The DARPA announcement further strengthens what has become a diversified neuropsychiatric platform that extends beyond traditional pharmaceutical development.
Today, NRx Pharmaceuticals is advancing:
- Late-stage pharmaceutical development through NRX-101 and preservative-free ketamine.
- Commercial interventional psychiatry clinics through HOPE Therapeutics.
- FDA-cleared AI-guided Transcranial Magnetic Stimulation technologies.
- Artificial intelligence-enabled mental health assessment platforms.
- Military and government research collaborations.
- Precision neuroplastic medicine combining advanced therapeutics with innovative medical technologies.
Together, these initiatives position the company across multiple segments of the rapidly evolving mental health market.
Looking Ahead
The selection of NRx Defense Systems by DARPA for contract negotiations represents another meaningful milestone in NRx Pharmaceuticals' ongoing evolution from a clinical-stage biotechnology company into a broader precision neuropsychiatry and commercial mental health organization.
If negotiations successfully result in a contract award, the SPARC-TMS program could further validate the company's integrated treatment strategy while expanding opportunities within military medicine and government-sponsored healthcare research.
Combined with continued progress across HOPE Therapeutics, advancement of NRX-101, commercialization initiatives, and expanding strategic partnerships, the DARPA announcement adds another potential catalyst for investors following NRx Pharmaceuticals as the company continues executing on its long-term growth strategy.
For more information on $NRXP visit: https://www.nrxpharma.com/ and https://compasslivemedia.com/case-study/nrx-pharmaceuticals/
Company Contact
NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)
Matthew Duffy – Chief Business Officer
Phone: (484) 254-6134
Email: mduffy@nrxpharma.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: CorporateAds
0 Comments
Latest on ncarol.com
- Stepping Off the Grid: Savista Retreat Announces New Experiential Packages in Jaipur for Travellers
- Where Is Your Faith The Movie and Sountrack
- Bynn Intelligence Ranks #1 in NIST Child Online Safety Evaluation for Ages 13–16
- Rev-O-Box™ Launches Reversible Shipping Box That Instantly Becomes a Premium Gift Box
- Las Vegas Estate Firm Ghandi Deeter Blackham Offers Insight on Tony Hsieh's Contested $500 Million Will
- Ms. Marie's Coffee Blend Launches Local Delivery Service Beginning in Lexington, North Carolina
- CCHR: Congressional Hearing Revives Lessons from MKULTRA Era – Why Past Psychiatric Human Rights Abuses Demand Vigilance Today
- Pacto Medical Wins Red Dot Design Concept Award 2026 for Slimshot® Compact Prefilled Syringe
- Heritage at Manalapan Introduces Luxury Single-Family Homes with Exceptional Value in One of Monmouth County's Most Desirable Locations
- Achugogo: Tale of the Spring Chaser Wins Inaugural TCCF Prize at Mifa Pitches, the Industry Market of the Annecy International Animation Film Festival
- Everything Policy Launches Madison, an AI Tool That Makes Legislation Readable for Students and Citizens
- TOLI North America Implements Modest Price Increase, Absorbing Majority of Costs
- Is the Market Missing One of the Most Undervalued Cybersecurity Companies on the Stock Market? Cycurion, Inc. (N A S D A Q: CYCU):
- Billion-Dollar Scale Global Technology Powerhouse Being Built with Expanding Government Contracts: Circle8 Group (N A S D A Q: CIRC)
- Nevada Boxing Hall of Fame Gears Up for Star-Studded 14th Annual Induction Gala Weekend
- New Thriller 'Counterframe' Explores the Hidden Vulnerabilities of Modern Society
- Award-Winning Heritage at South Brunswick Continues to Thrive as One of New Jersey's Premier New Home Communities
- Four Seasons Cleaners Debuts Santa Barbara County's First 24/7 Dry Cleaning Kiosk New self-service
- WhereTu Launches to Help Americans Build Successful Lives Abroad
- BoatRegistrationNumbers.com Launches Next-Generation Marine Lettering, Decals and Numbers Tool